Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

International Stem Cell Corp (ISCO)

International Stem Cell Corp (ISCO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

International Stem Cell Corp 9745 BUSINESSPARK AVENUE SAN DIEGO CA 92131 USA

www.internationalstemcell.com P: 760-940-6383

Description:

International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields.

Key Statistics

Overview:

Market Capitalization, $K 872
Enterprise Value, $K -708
Shares Outstanding, K 8,000
Annual Sales, $ 7,790 K
Annual Net Income, $ -130 K
Last Quarter Sales, $ 1,890 K
Last Quarter Net Income, $ -460 K
EBIT, $ -660 K
EBITDA, $ -470 K
60-Month Beta 0.50
% of Insider Shareholders 67.97%
% of Institutional Shareholders 0.00%
Float, K 0
% Float 0.00%
Short Volume Ratio 0.36

Growth:

1-Year Return -39.37%
3-Year Return -82.95%
5-Year Return -91.85%
5-Year Revenue Growth -29.76%
5-Year Earnings Growth 93.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.04 on 03/28/24
Latest Earnings Date 05/10/24 [--]
Earnings Per Share ttm -0.03
EPS Growth vs. Prev Qtr -100.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-150 on 07/29/15

ISCO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -3.77%
Profit Margin % -1.67%
Debt/Equity 0.00
Price/Sales 0.11
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -0.07
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar